We therefore sought to further characterize tumor sink effects, if any, in key healthy organs-at-risk of patients with metastatic castration-resistant prostate cancer (mCRPC) given two courses of 177-lutetium (177Lu)-PSMA-617 RLT. The gene discussed is FOLH1; the disease is neoplasm.